Analyst Ratings For Bio-Rad Laboratories (NYSE:BIO)
Today, Wells Fargo & Co lowered its price target on Bio-Rad Laboratories (NYSE:BIO) to $280.00 per share.
Some recent analyst ratings include
- 2/16/2018-CL King was Downgraded by analysts at CL King from a “Buy ” rating to a ” Neutral” rating.
- 9/18/2017-Deutsche Bank Reiterated Rating of Buy.
Recent Insider Trading Activity For Bio-Rad Laboratories (NYSE:BIO)
Bio-Rad Laboratories (NYSE:BIO) has insider ownership of 28.29% and institutional ownership of 64.05%.
- On 12/14/2017 Christine A Tsingos, CFO, sold 4,980 with an average share price of $249.40 per share and the total transaction amounting to $1,242,012.00.
- On 12/4/2017 Michael Crowley, EVP, sold 1,000 with an average share price of $258.39 per share and the total transaction amounting to $258,390.00.
- On 11/30/2017 James R. Stark, VP, sold 746 with an average share price of $270.51 per share and the total transaction amounting to $201,800.46.
- On 11/14/2017 Giovanni Magni, EVP, sold 2,400 with an average share price of $253.01 per share and the total transaction amounting to $607,224.00.
- On 8/11/2017 Michael Crowley, EVP, sold 700 with an average share price of $215.91 per share and the total transaction amounting to $151,137.00.
- On 3/7/2017 Michael Crowley, EVP, sold 300 with an average share price of $196.13 per share and the total transaction amounting to $58,839.00.
- On 11/9/2016 James R. Stark, VP, sold 1,299 with an average share price of $171.42 per share and the total transaction amounting to $222,674.58.
Recent Trading Activity for Bio-Rad Laboratories (NYSE:BIO)
Shares of Bio-Rad Laboratories closed the previous trading session at 271.40 up +17.20 6.77% with 265.885009765625 shares trading hands.